TORONTO–(BUSINESS WIRE)–Halo Labs Inc. (“Halo” or the “Company”) (NEO: HALO, OTCQX: AGEEF, Germany: A9KN) is pleased to announce it has entered into a definitive agreement (the “Agreement”) all of the common shares of Nasalbinoid Natural Devices Corp. (“Nasalbinoid” or “NND”) for C$5.1 million in Halo common shares at a deemed price of C$0.15 per share (a total of 34 million shares) (the “Acquisition”). The common shares issued by Halo in conjunction with the planned acquisition will be subje